Mantle Cell Lymphoma - Pipeline Review, H1 2014

Mantle Cell Lymphoma - Pipeline Review, H1 2014

Feb 2014 Global Markets Direct Lymphoma250 Pages Price :
$ 2000
Global Markets Direct’s, ‘Mantle Cell Lymphoma - Pipeline Review, H1 2014’, provides an overview of the Mantle Cell Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Mantle Cell Lymphoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Mantle Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Mantle Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Introduction
Global Markets Direct Report Coverage
Mantle Cell Lymphoma Overview
Therapeutics Development
Pipeline Products for Mantle Cell Lymphoma - Overview
Pipeline Products for Mantle Cell Lymphoma - Comparative Analysis
Mantle Cell Lymphoma - Therapeutics under Development by Companies
Mantle Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes
Mantle Cell Lymphoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Mantle Cell Lymphoma - Products under Development by Companies
Mantle Cell Lymphoma - Products under Investigation by Universities/Institutes
Mantle Cell Lymphoma - Companies Involved in Therapeutics Development
Amgen Inc.
Eli Lilly and Company
GlaxoSmithKline plc
Gilead Sciences, Inc.
Merck & Co., Inc.
Infinity Pharmaceuticals, Inc.
Piramal Enterprises Limited
Millennium Pharmaceuticals, Inc.
Novartis AG
Astellas Pharma Inc.
BioMarin Pharmaceutical Inc.
ImmunoGen, Inc.
Pfizer Inc.
Astex Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited
Cell Therapeutics, Inc.
Celgene Corporation
Onyx Pharmaceuticals, Inc.
Celldex Therapeutics, Inc.
Accentia Biopharmaceuticals, Inc.
Portola Pharmaceuticals, Inc.
Pharmacyclics, Inc.
Senesco Technologies, Inc.
Memgen, LLC.
Stemline Therapeutics, Inc.
Onconova Therapeutics, Inc.
LFB Biotechnologies, S.A.S
Advancell
Selvita S.A
AbbVie Inc.
Amgen Astellas BioPharma K.K.
Mantle Cell Lymphoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ibrutinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bortezomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bendamustine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pacritinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
abexinostat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
agatolimod sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dasiprotimut T - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AT-7519 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carfilzomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
idelalisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISF-35 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P-1446 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CTL-019 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vorinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buparlisib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lenalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY-2835219 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ublituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GS-9973 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SNS-01T - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRT-2070 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allogeneic CD19CAR-TCM cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEP-9722 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pevonedistat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CDX-1127 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rigosertib sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ON-013105 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
palbociclib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NSC-678515 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LEE-011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
duvelisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMN-673 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG-319 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMGN-529 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ABT-199 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
acadesine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SL-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
8-chloroadenosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SEL-120 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BLyS-Gelonin Fusion Toxin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ONC-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tretinoin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Andrographolide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
blinatumomab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mantle Cell Lymphoma - Recent Pipeline Updates
Mantle Cell Lymphoma - Dormant Projects
Mantle Cell Lymphoma - Discontinued Products
Mantle Cell Lymphoma - Product Development Milestones
Featured News & Press Releases
Dec 06, 2013: Spectrum Pharmaceuticals Highlights Abstracts On Marqibo at the 55th Annual Meeting of the American Society of Hematology
Nov 19, 2013: Impressive Results from ibrutinib Study Conducted at John Theurer Cancer Center Lead to FDA Approval of Imbruvica as a Single Agent for Patients with Mantle Cell Lymphoma
Nov 15, 2013: Diplomat receives limited distribution contract for IMBRUVICA
Nov 13, 2013: IMBRUVICA Capsules Now Approved in the U.S. for Mantle Cell Lymphoma Patients Who Have Received at Least One Prior Therapy
Nov 12, 2013: Senesco to Provide Update on Its Phase 1b/2a Trial Progress at 55th American Society of Hematology Annual Meeting
Oct 30, 2013: New Marketing Authorisation Application Submitted to EMA for Ibrutinib for the Treatment of Two Forms of Blood Cancer
Sep 26, 2013: John Theurer Cancer Center Announces Positive Results from Revlimid MCL-001 Study Leading to FDA Approval of First Oral Therapy for Refractory Mantle-Cell Lymphoma Patients
Aug 29, 2013: New Drug Application Filing for Ibrutinib Accepted in Two B-cell Malignancies by the U.S. FDA
Aug 22, 2013: Study of Mechanism of Action of Ibrutinib in Mantle Cell Lymphoma Published in Blood - Journal of the American Society of Hematology
Jul 10, 2013: New Drug Application for Ibrutinib Submitted to the U.S. FDA

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Table


Number of Products under Development for Mantle Cell Lymphoma, H1 2014
Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Development by Companies, H1 2014 (Contd..1)
Number of Products under Development by Companies, H1 2014 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Comparative Analysis by Unknown Stage Development, H1 2014
Products under Development by Companies, H1 2014
Products under Development by Companies, H1 2014 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2014
Mantle Cell Lymphoma - Pipeline by Amgen Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by Eli Lilly and Company, H1 2014
Mantle Cell Lymphoma - Pipeline by GlaxoSmithKline plc, H1 2014
Mantle Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by Merck & Co., Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by Piramal Enterprises Limited, H1 2014
Mantle Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by Novartis AG, H1 2014
Mantle Cell Lymphoma - Pipeline by Astellas Pharma Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by BioMarin Pharmaceutical Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by ImmunoGen, Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by Pfizer Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014
Mantle Cell Lymphoma - Pipeline by Cell Therapeutics, Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by Celgene Corporation, H1 2014
Mantle Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by Celldex Therapeutics, Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by Accentia Biopharmaceuticals, Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by Senesco Technologies, Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by Memgen, LLC., H1 2014
Mantle Cell Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by Onconova Therapeutics, Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by LFB Biotechnologies, S.A.S, H1 2014
Mantle Cell Lymphoma - Pipeline by Advancell, H1 2014
Mantle Cell Lymphoma - Pipeline by Selvita S.A, H1 2014
Mantle Cell Lymphoma - Pipeline by AbbVie Inc., H1 2014
Mantle Cell Lymphoma - Pipeline by Amgen Astellas BioPharma K.K., H1 2014
Assessment by Monotherapy Products, H1 2014
Number of Products by Stage and Target, H1 2014
Number of Products by Stage and Mechanism of Action, H1 2014
Number of Products by Stage and Route of Administration, H1 2014
Number of Products by Stage and Molecule Type, H1 2014
Mantle Cell Lymphoma Therapeutics - Recent Pipeline Updates, H1 2014
Mantle Cell Lymphoma - Dormant Projects, H1 2014
Mantle Cell Lymphoma - Discontinued Products, H1 2014

List of Chart


Number of Products under Development for Mantle Cell Lymphoma, H1 2014
Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Products, H1 2014
Assessment by Monotherapy Products, H1 2014
Number of Products by Top 10 Target, H1 2014
Number of Products by Stage and Top 10 Target, H1 2014
Number of Products by Top 10 Mechanism of Action, H1 2014
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
Number of Products by Top 10 Route of Administration, H1 2014
Number of Products by Stage and Top 10 Route of Administration, H1 2014
Number of Products by Top 10 Molecule Type, H1 2014
Number of Products by Stage and Top 10 Molecule Type, H1 2014

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top